Market News

Organizers secure three new dates for events in Japan, South East Asia and North America in response to COVID-19.

Company awarded US$5 million grant for clinical study of measles and rubella vaccination using Vaxxas’ high-density, micro-array patch.

This documentation will enable customers worldwide to leverage the D-Flex disposable pen system for their combination product development.

Postnova Analytics' CF2000 Centrifugal Field Flow Fractionation (CF3) system is delivering exciting new data to scientists developing drug delivery systems.

The trial is the first controlled trial in the US to evaluate the effect of IL-6 inhibition prospectively in COVID-19 patients.

A web-based means of finding the cleaning products to meet the challenges posed by cleanroom operations.

Pipeline diversification, emerging therapies and shifting customer demands are the real dynamics reshaping the contract manufacturing market, according to experts.

Appropriate asthma and COPD patients provided with a "more affordable alternative to appropriate".

Netherlands-based specialty pharmaceutical company Pharming has received US Food and Drug Administration (FDA) approval for its new biologics facility in the Netherlands which it says will ensure sufficient manufacturing capacity for its acute heredita...

Company launches BIOSTAT STR Generation 3 bioreactor with BIOBRAIN automation platform.

Phase III study evaluating Empliciti plus Revlimid and dexamethasone in patients with newly diagnosed, untreated multiple myeloma fails to meet primary endpoint.

Active pharmaceutical ingredients (APIs) nanoformed using the CESS process demonstrate promise for overcoming solubility and bioavailability challenges.

CDMO Bora Pharmaceuticals said Monday it has agreed to acquire GlaxoSmithKline's Mississauga, Ontario (Canada) facility, which produces approximately 50 different products for more than 100 markets worldwide.

Biotech firm Gilead Sciences said Monday it is set to acquire clinical-stage oncology specialist Forty Seven in a transaction worth $4.9 billion.

The company’s immediate priority is to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine.

Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, C2 Pharma, has expanded its advisory board with a new member.

The US Food and Drug Administration (FDA) accepts for review Pfizer and Eli Lilly's Biologics License Application (BLA) for tanezumab — a non-opioid treatment for patients with chronic pain due to moderate-to-severe osteoarthritis.

The White House task force and the US President will meet drug makers this afternoon to discuss "progress on a vaccine and cure".

Rescheduling will ensure all stakeholders can take part in a successful exhibition and conference.

A cooperation agreement between German pharma firm Merck KGaA and additive manufacturing specialist AMCM on 3D printing of tablets could eventually lead to scalable active pharmaceutical ingredient (API) formulation and faster, cheaper production, the ...

Agreement gives BIA Separations access to proprietary technology to better preserve integrity, infectivity and potency of immunoaffinity-purified viral vectors for gene therapy.

The study will evaluate the efficacy of SJX-653 in reducing the frequency and severity of VMS due to menopause, as well as improving measures of sleep and quality of life.

Unlocking the potential of Raman spectroscopy as a high throughput analytical technique for monitoring cell culture in mini bioreactors.

Sanofi's plans to create a European company to manufacture and market active pharmaceutical ingredients (APIs) should help to balance the region's heavy reliance on sourcing them from Asian markets, the French pharmaceutical firm said Monday.

Beovu is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on 3-month dosing intervals immediately after the loading phase.

The future of value-added medicines will see gamification transforming the engagement of therapies.

The investment will support continued expansion into the fast-growing gene therapy segment, including new developments that will enable a range of best-in-class solutions for viral manufacturing.

The expansion will enable Putnam Associates to access the European market and to offer more localised support to its clients.

Deal sees 62 brands in multiple therapy areas and a manufacturing plant transfer to the company

Investment in resources to meet demand for large-scale supply of patented biocompatible surfactant.

Event move ensures extra precautions and safety measures taken

The company aims to simplify its customers’ work and thus help them to achieve medical progress and make innovative medicines available faster.

The inspection was triggered by data generated by MedPharm as part of a client’s ANDA for a generic topical product.

The changing opportunities are attributed to rising GMP standards and increased regional harmonization.

Stevanato and Pfeiffer Vacuum will provide biopharma companies with advanced container closure integrity analysis and testing protocols.

Innovations across primary and secondary packaging, drug delivery devices, and machinery acknowledged in Exhibitor Innovations, with Health Product Awards for patient-centricity and eco-design.

Zenith Technologies CEO, Joe Haugh, takes us through how the business has evolved this year, to better meet the needs of its customers, as well as the trends they see shaping the industry through 2020 and beyond.

CEO says the acquisition of Consort Medical will help to create a leading advanced delivery systems company.

The facility will triple the company’s cGMP clinical trial manufacturing capacity.

TwinMax enabes delivery of doses up to 100 mg formulated as drug alone or engineered particles.

The additional capacity will provide customers with shorter lead times and reduced transportation costs.

Bundling of competencies optimizes workflow of customer projects.

Trijardy XR is a once-daily therapy combining three well-established treatments in one pill.

Agreement will facilitate clinical trial translations in China.

Pharmapack also identifies waste management and the use of blockchain as key trends for the year ahead.

If proven safe and effective, mAb CIS43LS might be used prophylactically by tourists, medical workers or military personnel who travel to areas where malaria is common.

€250 million to be invested during the 2019-2022 period in new facility bridging research and manufacturing.

The programme will include the launch of next-generation respiratory inhalers, which will use near-zero Global Warming Potential propellants.

The $470 million investment will support a state-of-the-art facility that produces injectable products and delivery devices.

No need to draw blood; researchers develop smart technology to diagnose diabetes and treat diabetic retinopathy.

The company targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumours for attack and destruction by the immune system.

The potential acquisition will see UK CDMO NextPharma develop and broaden its technology offering into lipid-based finished dosage forms

First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities.

Business to focus on intelligent and sustainable technologies.

BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.

The French National Agency for Medicines and Health Product Safety (ANSM) has agreed that Innate Pharma’s Tellomak (lacutamab) Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) in ...

PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases.

Multiple options provide increased flexibility for sponsors.

The product being developed will use proprietary drug formulation technology platform Arestat to deliver new reformulations of existing, complex products.

India’s Lupin Pharmaceuticals warned Monday it could face regulatory sanctions from the US Food and Drug Administration over its Tarapur active pharmaceutical ingredient (API) manufacturing facility.

CPHI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPHI, including CPHI North America—the only event to bring the entire North American pharmac...

Platform gives researchers access to previously undiscovered data to guide evaluation and validation of new drug targets, pathogen identification, disease diagnosis, and the advancement of regenerative medicine.

The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.

End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.

Expands company's capacity and capability for this novel modality, providing a one-stop shop from preclinical to commercial.

Drug industry expectations of packaging are evolving with developers now seeking techs that help patients get more from their medicines.

Mutations in the RIPK1 gene responsible for CRIA syndrome.

Capacity to serve global late-stage development and commercial manufacturing of monoclonal antibody drug substance to support new product launches.

Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.

Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy.

Botox and Botox Cosmetic (onabotulinumtoxinA) hold 14 therapeutic and aesthetic indications combined, more than any other neurotoxin in the world.

Next-generation pharmaceutical supply-chain security for tracking product from plant to patient.

Customers and partners look set to benefit from reduced development times and costs of medical drugs.

The investment enhances the supply chain robustness of products manufactured for the makers of solid oral dosage products.

Experts suggest the continued goal of aligning India to Western regulatory standards will help the country sustain significant increases in exports.

CMO's customer base has grown by more than 25% in 2019 alone, and investment and demand for services is estimated to increase output by another 25-30% in 2020.

The past 12 months have been busy as many companies fought to comply with serialization regulations.

Represents the first biopackaging of its kind made of renewable raw materials.

New CTSuccess service helps to reduce the risk of delays and budget overspend.

The fast-dispersing Zydis formulation could increase compliance with Medication-Assisted Treatment and thus better clinical outcomes.

Smart tags on pills set to improve supply chain security and patient adherence.

The US pharmaceutical industry continues to lead its global peers in terms of innovation and competitiveness, while still ranking high in overall growth potential despite its mature status, according to the results of a survey of 350 global pharmaceuti...

Installation of a SprayVIEW system will help the CDMO to support customers in both innovative and generic inhalation and nasal product development.

Lead asset THOR-707 being explored across multiple solid tumor types alone and in combination with immune checkpoint inhibitors and other future IO combinations.

Expansion increases capacity for the company's topical and transdermal services, as well as dedicated innovation, microbiology and histology laboratories.

Pharmapack 2020 gathering top specialists and pioneers to exchange their vision on best strategies to tackle key challenges.

New innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives.

Lilly Gateway Labs will provide biotech companies direct access to Lilly scientists and expertise.

Unprecedented levels of investment cited as a major force driving the expansion.

The financial backing will help the company to develop a new generation of microbial air monitors that enables continuous monitoring as demanded by the Annex 1 revision.

ClearMixx performs liquid/liquid and powder/liquid mixing, with a dispersion plate able to efficiently mix the most challenging buffer, media and biopharmaceutical ingredients.

Content sessions identify value-added medicines, preventive drugs, early diagnostics and patient experience as some of the trends for the year ahead.

The largest area of growth has been within biotechnology companies, where job openings increased by 35%.

The company's diabetes nutrition drink, Celevida, is formulated to help manage blood glucose levels.

The rise in exports growth potential is believed to be in response to concerted reforms by the CDSCO and industry quality improvements in the last few years.

Company's multimillion euro investment will enable it to meet growing market demands from clients providing cancer treatments.

The new center will provide expertise in critical analytical processes and specialized workflows.

The device's blister is designed to provide flexibility to pharmaceutical partners delivering a wide range of inhaled drugs for both acute and chronic respiratory treatments.

The CDMO offers to acquire Consort Medical to become a Top Five global CDMO player.

Marks the latest step in the company’s ongoing efforts to engage with other organisations working to tackle antimicrobial resistance.

New models can help researchers investigate disease development and find new treatment approaches.

The device supports the new EU GMP Annex 1 requirements.

China-US trade challenges has led to de-risking by pharma companies.

Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.

But personalized medicines will require new logistics and manufacturing systems.

Partnership will combine capabilities and expertise in Europe and India to build a new facility dedicated to injectable formulations to supply demand from Europe and overseas territories.

Demand for biological manufacturing is growing faster than capacity growth.

Company to reach 250 employees by year end to meet growing drug product manufacturing demand.

Company's strategic move reflects its expectation of short-run aseptic liquid filling to continue to drive pharmaceutical growth.

A shortage of qualified personnel may be a drag factor in cell and gene therapies; in China 100,00L of capacity will need to be added every year to meet bio demand.

Services including method development, method validation, and stability program design and implementation.

15,000 sq. ft of laboratory and office space will enable continued growth and development of the company’s integrated desktop platform for DNA synthesis.

Free webinar to discuss the benefits of a collaborative approach to implementing an electronic batch record platform.

CDMO to invest over €3 million in GMP facility expansion.

The investment will allow the CDMO to take on new projects, as well as bolster the company's chemistry development capabilities.

Germany establishes itself as Europe's leading pharma market in 2019.

Outsourcing, biologics, generics and patient compliance look set to get tongues wagging at this year's CPHI WW.

Highest level of data integrity as requested by regulatory authorities.

CPHI Worldwide's Annual Report suggests repeat offenders of regulatory infringements should be barred from importing into the US.

Leaders in atrial fibrillation and wearable technology to develop educational content around atrial fibrillation to help identify and support those at increased risk of stroke.